Pharmacoresistance in epilepsy: A pilot PET study with the P-glycoprotein substrate R-[11C]verapamil

Epilepsia

Volumn 48, Issue 9, 2007, Pages 1774-1784

  Langer, Oliver ^a,b   Bauer, Martin ^a   Hammers, Alexander ^c,d   Karch, Rudolf ^a   Pataraia, Ekaterina ^a   Koepp, Matthias J ^d   Abrahim, Aiman ^a   Luurtsema, Gert ^e   Brunner, Martin ^a   Sunder Plassmann, Raute ^a   Zimprich, Friedrich ^a   Joukhadar, Christian ^a   Gentzsch, Stephan ^a   Dudczak, Robert ^a   Kletter, Kurt ^a   Müller, Markus ^a   Baumgartner, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptic drugs; Pharmacoresistance; Positron emission tomography; R 11C verapamil; Temporal lobe epilepsy P glycoprotein

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GLYCOPROTEIN P; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; VALPROIC ACID; VERAPAMIL;

ADULT; ARTICLE; BRAIN REGION; BRAIN SIZE; CHILD; CHOROID PLEXUS; CLINICAL ARTICLE; DISTRIBUTION VOLUME; ENZYME ACTIVITY; EPILEPSY; EPILEPTIC FOCUS; EPILEPTOGENESIS; FEMALE; HEMISPHERE; HIPPOCAMPUS; HUMAN; MALE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; SEIZURE; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE; TEMPORAL LOBE EPILEPSY; WILCOXON SIGNED RANKS TEST;

ADULT; AGE OF ONSET; BRAIN; CARBON RADIOISOTOPES; DRUG RESISTANCE; EPILEPSIES, PARTIAL; FEMALE; FUNCTIONAL LATERALITY; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TEMPORAL LOBE; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 34548413773     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01116.x     Document Type: Article

References (47)

1. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, van Vliet EA, Scheffer GL, Scheper RJ, Van Der Valk P, Baayen JC, Troost D 2004) Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45 : 441 451.
2. Ashburner J, Friston KJ 2005) Unified segmentation. Neuroimage 26 : 839 851.
3. Baltes S, Potschka H, Luna Tortos C, Fedrowitz M, Löscher W 2006) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins MRP1 and MRP2 in a number of in vitro and in vivo transport assays. Journal of Pharmacological Experiment and Therory : doi:10.1124/jpet.106.102491.
4. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T 2002) Reversal of multidrug resistance: lessons from clinical oncology. Novartis Foundation Symposium 243 : 83 96 discussion 96-102, 180-105.
5. Bertoldo A, Peltoniemi P, Oikonen V, Knuuti J, Nuutila P, Cobelli C 2001) Kinetic modeling of [(18)F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model. American Journal of Physiology, Endocrinology, and Metabolism 281 : E524 536.
6. Bourgeois BFD (2001) General concepts of medical intractability. In Lüders HO, Comair YG (Eds) Epilepsy surgery. Lippincott Williams & Wilkins, Philadelphia, pp. 63 68.
7. Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Müller M 2005) Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics 78 : 182 190.
8. Cobelli C, Foster D, Toffolo G (2000) Tracer kinetics in biomedical research: from data to model. Kluwer Academic/Plenum, New York.
9. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D 2001) Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42 : 1501 1506.
10. Elsinga PH, Franssen EJ, Hendrikse NH, Fluks L, Weemaes AM, Van Der Graaf WT, de Vries EG, Visser GM, Vaalburg W 1996) Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. Journal of Nuclear Medicine 37 : 1571 1575.
11. Franssen EJ, Luurtsema G, Lammertsma AA 2006) Imaging P-glycoprotein at the human blood-brain barrier. Clinical Pharmacology and Therapy 80 : 302 303 author reply 303-304.
12. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, Mitchell TN, Brooks DJ, Duncan JS 2003) Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human Brain Mapping 19 : 224 247.
13. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van Der Graaf WT, Willemsen AT, Vaalburg W, Franssen EJ 1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. British Journal of Pharmacology 124 : 1413 1418.
14. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U 2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences of USA 97 : 3473 3478.
15. Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, Fukumura T, Nakao R, Suzuki K, Suhara T 2006) Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. Journal of Nuclear Medicine 47 : 1531 1537.
16. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH 2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Annals of Neurology 57 : 176 179.
17. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, Suhara T 2006) In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. Journal Pharmacology and Experimental Therapeutics 316 : 647 653.
18. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, et al 1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. Journal of Cerebral Blood Flow and Metabolism 10 : 740 747.
19. Löscher W. (2005) How to explain multidrug resistance in epilepsy? Epilepsy Current 5 : 107 112.
20. Löscher W, Potschka H 2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. Journal of Pharmacology and Experimental Therapeutics 301 : 7 14.
21. Löscher W, Potschka H 2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2 : 86 98.
22. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA 2006) Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[(11)C]verapamil and PET. Journal of Cerebral Blood Flow Metabolism : doi: 10.1038/sj.jcbfm. 9600349.
23. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ 2005) Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nuclear Medicine and Biology 32 : 87 93.
24. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK 2001) Carbamazepine is not a substrate for P-glycoprotein. British Journal of Clinical Pharmacology 51 : 345 349.
25. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF 2000) Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics 293 : 376 382.
26. Potschka H, Löscher W 2001) In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 42 : 1231 1240.
27. Potschka H, Fedrowitz M, Löscher W 2001) P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12 : 3557 3560.
28. Potschka H, Fedrowitz M, Löscher W 2003) Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. Journal of Pharmacology and Experimental Therapeutics 306 : 124 131.
29. Potschka H, Baltes S, Löscher W 2004) Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Research 58 : 85 91.
30. Rambeck B, Jurgens UH, May TW, Pannek HW, Behne F, Ebner A, Gorji A, Straub H, Speckmann EJ, Pohlmann-Eden B, Löscher W 2006) Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 47 : 681 694.
31. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D 1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proceedings of the National Academy of Sciences of USA 96 : 3900 3905.
32. Remy S, Beck H 2006) Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129 : 18 35.
33. Robb RA. (2001) The biomedical imaging resource at Mayo Clinic. IEEE Transactions on Medical Imaging 20 : 854 867.
34. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD 2005) Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clinical Pharmacology and Therapeutics 77 : 503 514.
35. Siarheyeva A, Lopez JJ, Glaubitz C 2006) Localization of multidrug transporter substrates within model membranes. Biochemistry 45 : 6203 6211.
36. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM 2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine 348 : 1442 1448.
37. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ 2005) Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 46 : 643 647.
38. Sisodiya SM, Bates SE 2006) Treatment of drug resistance in epilepsy: one step at a time. Lancet Neurology 5 : 380 381.
39. Sisodiya SM, Heffernan J, Squier MV 1999) Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 10 : 3437 3441.
40. Sunder-Plassmann R, Rieger S, Endler G, Brunner M, Müller M, Mannhalter C 2005) Simultaneous analysis of MDR1 C3435T, G2677T/A, and C1236T genotypes by multiplexed mutagenically separated PCR. Clinical Chemistry and Laboratory Medicine 43 : 192 194.
41. Syvänen S, Blomquist G, Sprycha M, Urban Hoglund A, Roman M, Eriksson O, Hammarlund-Udenaes M, Långström B, Bergström M 2006a) Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 32 : 1134 1141.
42. Syvänen S, Xie R, Sahin S, Hammarlund-Udenaes M 2006b) Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharmaceutical Research 23 : 705 717.
43. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM 2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 : 219 234.
44. Tan NC, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF, Mulley JC, Berkovic SF 2004) Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63 : 1090 1092.
45. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C 1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 : 1 6.
46. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ 2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clinical Pharmacology and Therapeutics 79 : 540 548.
47. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C 2004) Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63 : 1087 1089.